四川九章生物化工科技发展有限公司

Sichuan Jiuzhang Biotechnology (formerly Sichuan Jiuzhang Biological Chemical Technology Development) is a Chinese biopharmaceutical company founded in 1999 that specializes in the research, development, and commercialization of innovative small molecule natural drugs. The company's core focus is on chlorogenic acid (CHA), a natural plant-derived compound, which it has developed as a first-in-class therapeutic for major diseases including glioblastoma multiforme (GBM), non-small cell lung cancer (NSCLC), and autoimmune disorders. Utilizing its proprietary platform for the extraction, separation, and purification of easily oxidizable natural products, Jiuzhang Biotechnology has achieved 99.9% purity for its pharmaceutical-grade chlorogenic acid. The company's lead candidate, injectable chlorogenic acid, is currently in Phase II/III clinical trials for recurrent glioblastoma and is being evaluated for other oncology and immunological indications.